Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Verastem, Inc. (VSTM) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including Forms 8-K, 10-K, 10-Q, and registration statements filed with the U.S. Securities and Exchange Commission. Verastem’s filings document its status as a Nasdaq-listed biopharmaceutical issuer focused on RAS/MAPK pathway-driven cancers, with common stock registered on The Nasdaq Capital Market under the symbol VSTM.
Recent Form 8-K reports highlight several important areas for investors: underwritten public offerings of common stock and pre-funded warrants under an effective shelf registration statement on Form S-3, preliminary and updated clinical data for the KRAS G12D inhibitor VS-7375, and company communications regarding AVMAPKI FAKZYNJA CO-PACK, an FDA-approved combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. These current reports also reference updated corporate presentations and conference materials that outline Verastem’s pipeline and strategy.
For a biopharmaceutical company like Verastem, periodic reports such as Forms 10-K and 10-Q (when available) typically contain detailed information on research and development spending, commercialization activities for AVMAPKI FAKZYNJA CO-PACK, risk factors related to oncology drug development, and the status of key clinical programs such as RAMP 301, RAMP 205, and VS-7375-101. Capital structure changes, including equity offerings and warrant terms, are also described in registration statements and accompanying exhibits.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain complex sections in plain language, highlight material events, and surface items of interest such as financing transactions, clinical trial disclosures, and changes in capital markets activity. Users can quickly scan new 8-Ks, 10-Qs, and 10-Ks for Verastem, review details of public offerings and warrant structures, and explore how regulatory filings align with the company’s oncology pipeline and commercial strategy.
Verastem, Inc. (VSTM) insider Daniel Calkins has filed notice of a planned stock sale under Rule 144. The filing covers up to 5,039 shares of Verastem common stock to be sold through Shareworks by Morgan Stanley on or about 01/12/2026 on the NASDAQ, with an aggregate market value of $36,069.00. The filing notes that 66,776,006 shares of Verastem common stock were outstanding.
The 5,039 shares to be sold were acquired on 01/10/2025 through the vesting of a restricted stock unit award from Verastem, Inc. For additional context, during the past three months Daniel Calkins sold 80 Verastem shares on 12/24/2025 for gross proceeds of $628.80.
Verastem, Inc. insider Daniel Paterson has filed a Form 144 to sell 10,321 shares of Verastem common stock. The planned sale has an aggregate market value of $73,851.00 based on the figures provided, with the shares to be sold through Shareworks by Morgan Stanley on the NASDAQ, with an approximate sale date of 01/12/2026. Verastem had 66,776,006 common shares outstanding according to the notice.
The 10,321 shares proposed for sale were acquired on 01/10/2025 through the vesting of a restricted stock unit award from Verastem, with the same date listed as the payment date and the consideration described as N/A. The filing also lists multiple prior sales of Verastem securities by Daniel Paterson over the past three months, including 3,299 shares sold on 11/03/2025 for $32,146.00 and 2,000 shares sold on 12/11/2025 for $20,000.00.
Verastem, Inc. reported an insider share sale by its President and CEO, Dan Paterson. On January 12, 2026, he sold 10,321 shares of Verastem common stock at a price of $7.16 per share.
According to the disclosure, this sale was made to satisfy statutory tax withholding requirements tied to the vesting of restricted stock units, meaning it was connected to equity compensation rather than an open-market discretionary sale. After this transaction, Paterson beneficially owned 400,104 shares of Verastem common stock directly.
Verastem, Inc. Chief Financial Officer Form 4 filing reports a small, routine sale of company stock tied to equity compensation. On January 12, 2026, the CFO, Daniel Calkins, sold 5,039 shares of Verastem common stock at $7.16 per share. According to the footnote, this sale was made to satisfy statutory withholding tax requirements in connection with the vesting of restricted stock units, rather than as a discretionary sale of shares.
Following this transaction, the reporting person beneficially owned 104,719 shares of Verastem common stock, held directly. The filing is made by a single reporting person in the capacity of Chief Financial Officer and reflects standard administration of equity awards.
Verastem, Inc. filed a current report to inform investors that it has posted an updated corporate presentation on its website. The updated presentation, dated January 8, 2026, is also included as Exhibit 99.1.
This type of disclosure is meant to provide the market with the same information that the company is sharing in its investor materials, helping ensure all investors have equal access to the updated corporate overview and strategy details.
Verastem, Inc. reported an insider equity award for Michael Kauffman, who serves as both a director and President of Development. On January 6, 2026, he received a stock option covering 200,000 shares of Verastem common stock with an exercise price of $6.88 per share, held directly.
The option vests over three years: 33.33% of the shares vest on the first anniversary of the January 6, 2026 grant date, and an additional 8.33% vest at the end of each three‑month period thereafter until the third anniversary. Vesting requires that Kauffman continue to serve as an employee or other service provider to Verastem on each vesting date.
Verastem, Inc. director reports small share sale for tax withholding
A Verastem, Inc. director reported selling 592 shares of common stock on 12/16/2025 at a price of $9.14 per share. After this transaction, the director beneficially owns 101,147 shares of Verastem common stock in direct form.
The filing explains that the shares sold were used to satisfy statutory tax withholding obligations that arose when restricted stock units vested, meaning the transaction relates to equity compensation rather than a discretionary open‑market sale of the director’s investment position.
Verastem, Inc. reported that its President and CEO, who also serves as a director, carried out a small sale of company stock. On 12/16/2025, the executive sold 393 shares of Verastem common stock at a price of $9.14 per share. According to the filing, this sale was made to satisfy statutory withholding requirements related to the vesting of restricted stock units, meaning it was tied to equity compensation rather than an open-market portfolio decision. After this transaction, the executive still beneficially owns 410,425 shares of Verastem common stock, held directly.
Verastem, Inc. director reports small stock sale for tax withholding
A director of Verastem, Inc. (VSTM) reported the sale of 283 shares of common stock on 12/16/2025 at a price of $9.14 per share. After this transaction, the reporting person beneficially owns 41,678 shares of Verastem common stock in direct ownership. According to the footnote, the sale was made to cover statutory tax withholding obligations related to the vesting of restricted stock units, rather than as a discretionary open-market sale.
Verastem, Inc. reported that its President and CEO, who is also a director, sold common stock in two transactions under a Rule 10b5-1 trading plan.
On December 10, 2025, the insider sold 2,000 shares of Verastem common stock at $10.07 per share, and on December 11, 2025, sold another 2,000 shares at $10.00 per share. Following these sales, the insider directly beneficially owned 410,818 shares of Verastem common stock.
FAQ
What is the current stock price of Verastem (VSTM)?
What is the market cap of Verastem (VSTM)?
